arrow_back Back Filing freshness 10-Q Q2 FY2025 SEC EDGAR

LISATA THERAPEUTICS, INC.

LSTA
$1.44 ▼ -0.06 (-4.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

LISATA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.1M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -54.8%
FCF / Share $-0.29
Trailing P/E
Price / Book 1.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-2.93M
↑ +37.1%
Operating Margin Operating profit as % of sales
-494.9%
↓ -311.4%
FCF / Share Free cash flow per share
$-0.29
↑ +15.0%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters